Insider · CIK 0001744749

Biller Jonathan

Reports to the SEC for 3 companies · BOSTON, MA

sec.gov

Transactions

Companies

Filings

CIK

0001744749

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-02-25	VRTXVERTEX PHARMACEUTICALS INC / MAS Sale	EVP and Chief Legal Officer	SSale	−945 sh	$486.35	−$460K	13,659
2026-02-24	VRTXVERTEX PHARMACEUTICALS INC / MAF Tax Payment	EVP and Chief Legal Officer	FTax Payment	−1,144 sh	$485.11	−$555K	14,604
2026-02-18	VRTXVERTEX PHARMACEUTICALS INC / MAS Sale	EVP and Chief Legal Officer	SSale	−1,244 sh	$473.68	−$589K	15,748
2026-02-17	VRTXVERTEX PHARMACEUTICALS INC / MAA Award	EVP and Chief Legal Officer	AAward	+4,135 sh	—	—	20,973
2026-02-17	VRTXVERTEX PHARMACEUTICALS INC / MAF Tax Payment	EVP and Chief Legal Officer	FTax Payment	−1,505 sh	$483.75	−$728K	19,468
2026-02-17	VRTXVERTEX PHARMACEUTICALS INC / MAS Sale	EVP and Chief Legal Officer	SSale	−2,476 sh	$489.46	−$1.21M	16,992
2026-02-13	VRTXVERTEX PHARMACEUTICALS INC / MAS Sale	EVP and Chief Legal Officer	SSale	−988 sh	$499.00	−$493K	16,838
2026-02-13	VRTXVERTEX PHARMACEUTICALS INC / MAF Tax Payment	EVP and Chief Legal Officer	FTax Payment	−2,993 sh	$487.76	−$1.46M	17,826
2026-02-11	VRTXVERTEX PHARMACEUTICALS INC / MAS Sale	EVP and Chief Legal Officer	SSale	−1,925 sh	$460.43	−$886K	20,819
2026-02-10	VRTXVERTEX PHARMACEUTICALS INC / MAF Tax Payment	EVP and Chief Legal Officer	FTax Payment	−1,630 sh	$468.41	−$764K	22,744
2026-01-22	VRTXVERTEX PHARMACEUTICALS INC / MAA Award	EVP and Chief Legal Officer	AAward	+6,294 sh	—	—	21,600
2026-01-22	VRTXVERTEX PHARMACEUTICALS INC / MAA Award	EVP and Chief Legal Officer	AAward	+2,774 sh	—	—	24,374
2025-12-03	VRTXVERTEX PHARMACEUTICALS INC / MAS Sale	EVP and Chief Legal Officer	SSale	−347 sh	$449.00	−$156K	15,306
2025-10-02	VRTXVERTEX PHARMACEUTICALS INC / MAS Sale	EVP and Chief Legal Officer	SSale	−694 sh	$404.21	−$281K	15,653
2025-10-01	VRTXVERTEX PHARMACEUTICALS INC / MAF Tax Payment	EVP and Chief Legal Officer	FTax Payment	−1,259 sh	$400.00	−$504K	16,347
2025-02-18	VRTXVERTEX PHARMACEUTICALS INC / MAS Sale	EVP and Chief Legal Officer	SSale	−1,657 sh	$455.06	−$754K	17,606
2025-02-14	VRTXVERTEX PHARMACEUTICALS INC / MAF Tax Payment	EVP and Chief Legal Officer	FTax Payment	−1,504 sh	$463.46	−$697K	19,263
2025-02-12	VRTXVERTEX PHARMACEUTICALS INC / MAA Award	EVP and Chief Legal Officer	AAward	+4,437 sh	—	—	20,767
2025-02-11	VRTXVERTEX PHARMACEUTICALS INC / MAS Sale	EVP and Chief Legal Officer	SSale	−3,433 sh	$459.87	−$1.58M	16,330
2025-02-10	VRTXVERTEX PHARMACEUTICALS INC / MAF Tax Payment	EVP and Chief Legal Officer	FTax Payment	−1,632 sh	$467.98	−$764K	19,763
2025-02-04	VRTXVERTEX PHARMACEUTICALS INC / MAA Award	EVP and Chief Legal Officer	AAward	+4,744 sh	—	—	21,395
2024-10-02	VRTXVERTEX PHARMACEUTICALS INC / MAS Sale	EVP and Chief Legal Officer	SSale	−999 sh	$461.66	−$461K	16,651
2024-10-01	VRTXVERTEX PHARMACEUTICALS INC / MAF Tax Payment	EVP and Chief Legal Officer	FTax Payment	−630 sh	$466.84	−$294K	17,650
2024-02-12	VRTXVERTEX PHARMACEUTICALS INC / MAS Sale	EVP and Chief Legal Officer	SSale	−1,738 sh	$418.77	−$728K	18,280
2024-02-09	VRTXVERTEX PHARMACEUTICALS INC / MAF Tax Payment	EVP and Chief Legal Officer	FTax Payment	−1,588 sh	$422.74	−$671K	20,018
2024-02-07	VRTXVERTEX PHARMACEUTICALS INC / MAA Award	EVP and Chief Legal Officer	AAward	+4,743 sh	—	—	21,606
2024-02-06	VRTXVERTEX PHARMACEUTICALS INC / MAA Award	EVP and Chief Legal Officer	AAward	+6,294 sh	—	—	16,863
2023-10-02	VRTXVERTEX PHARMACEUTICALS INC / MAS Sale	EVP and Chief Legal Officer	SSale	−610 sh	$346.76	−$212K	10,569
2023-09-29	VRTXVERTEX PHARMACEUTICALS INC / MAF Tax Payment	EVP and Chief Legal Officer	FTax Payment	−408 sh	$350.72	−$143K	11,179
2023-02-01	VRTXVERTEX PHARMACEUTICALS INC / MAA Award	EVP and Chief Legal Officer	AAward	+6,293 sh	—	—	11,587
2022-09-19	VRTXVERTEX PHARMACEUTICALS INC / MAA Award	EVP and Chief Legal Officer	AAward	+5,294 sh	—	—	5,294
2022-03-01	AGIOAGIOS PHARMACEUTICALS, INC. · Stock options (right to buy)A Award	Chief Financial Officer	AAward	+41K sh	—	—	41,000
2022-03-01	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsA Award	Chief Financial Officer	AAward	+11.5K sh	—	—	11,500
2022-02-22	AGIOAGIOS PHARMACEUTICALS, INC.F Tax Payment	Chief Financial Officer	FTax Payment	−2,688 sh	$29.08	−$78.2K	22,953
2022-02-18	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+8,523 sh	—	—	25,641
2022-02-18	AGIOAGIOS PHARMACEUTICALS, INC. · Performance share unitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−8,523 sh	—	—	8,522
2022-02-10	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−3,667 sh	—	—	7,333
2022-02-10	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+3,667 sh	—	—	18,467
2022-02-10	AGIOAGIOS PHARMACEUTICALS, INC.F Tax Payment	Chief Financial Officer	FTax Payment	−1,349 sh	$31.43	−$42.4K	17,118
2021-12-03	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+5,753 sh	—	—	16,623
2021-12-03	AGIOAGIOS PHARMACEUTICALS, INC.F Tax Payment	Chief Financial Officer	FTax Payment	−1,823 sh	$35.88	−$65.4K	14,800
2021-12-03	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−5,753 sh	—	—	5,753
2021-02-10	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsA Award	Chief Financial Officer	AAward	+11K sh	—	—	11,000
2021-02-10	AGIOAGIOS PHARMACEUTICALS, INC. · Stock option (right to buy)A Award	Chief Financial Officer	AAward	+44K sh	—	—	44,000
2020-12-03	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−5,753 sh	—	—	11,506
2020-12-03	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+5,753 sh	—	—	11,747
2020-12-03	AGIOAGIOS PHARMACEUTICALS, INC.F Tax Payment	Chief Financial Officer	FTax Payment	−1,707 sh	$45.87	−$78.3K	10,040
2020-04-14	AGIOAGIOS PHARMACEUTICALS, INC.F Tax Payment	Chief Financial Officer	FTax Payment	−2,529 sh	$40.64	−$103K	5,994
2020-04-13	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+8,523 sh	—	—	8,523
2020-04-13	AGIOAGIOS PHARMACEUTICALS, INC. · Performance share unitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−8,523 sh	—	—	17,045

Recent filings

Accepted (ET)
Feb 264
Biller Jonathan0000875320-26-000108
SEC(opens sec.gov)
Feb 194
Biller Jonathan0000875320-26-000084
SEC(opens sec.gov)
Feb 184
Biller Jonathan0000875320-26-000064
SEC(opens sec.gov)
Feb 124
Biller Jonathan0000875320-26-000040
SEC(opens sec.gov)
Jan 264
Biller Jonathan0000875320-26-000014
SEC(opens sec.gov)
Dec 54
Biller Jonathan0000875320-25-000240
SEC(opens sec.gov)
Oct 34
Biller Jonathan0000875320-25-000224
SEC(opens sec.gov)
Feb 194
Biller Jonathan0000875320-25-000085
SEC(opens sec.gov)
Feb 144
Biller Jonathan0000875320-25-000063
SEC(opens sec.gov)
Feb 124
Biller Jonathan0000875320-25-000039
SEC(opens sec.gov)

Companies

Address

C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE

BOSTON, MA, 02210